TRIPLE-NEGATIVE BREAST CANCER (TNBC)

This study tests whether adding the experimental drug onvansertib to standard chemotherapy (paclitaxel) is safe and effective for people with triple-negative breast cancer that has spread to other parts of the body. About 50 adults with advanced disease are participating. The goa…

This early-phase study tests an experimental oral drug, BBI-355, in people with advanced solid tumors (like certain breast, ovarian, lung, and other cancers) that have extra copies of certain genes (oncogene amplifications). The study aims to find the safest dose and see if BBI-3…

This early-stage trial tests a new two-part treatment for people with advanced breast cancer that has not responded to standard therapies. Participants receive a single infusion of their own engineered immune cells (CLBR001) followed by cycles of a biologic drug (ABBV-461). The m…

This early-phase study tests the safety of a new drug called AB598, given alone or with other treatments, in about 40 people with advanced solid tumors (e.g., lung, bladder, breast, or ovarian cancer). The main goal is to see if the drug is safe and tolerable. Participants must h…

This study tests whether a combination of two chemotherapy drugs, liposomal doxorubicin and carboplatin, can lower the chance of cancer returning in people with early-stage triple negative breast cancer. About 30 participants who have already had surgery will receive the treatmen…

This early-phase study tests an experimental drug called RNDO-564, alone or with pembrolizumab, in adults with advanced solid tumors (like bladder, lung, or breast cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the best dose,…

This study looks at how well the body of women with early triple-negative breast cancer can switch between using fat and sugar for energy, a trait called metabolic flexibility. Researchers will measure this at diagnosis, after chemotherapy, after surgery, and after a 12-week exer…